Details

Autor(en) / Beteiligte

• Chen, Zhenying
• Yang, Apeng
• Zhang, Jiaying
• Chen, Aihong
• Zhang, Yuanqing
• Huang, Chao
• Chen, Shaoming
• Yao, Shaobo
• Miao, Weibing

Titel

CXCR4-Directed PET/CT with [68Ga]Pentixafor in Central Nervous System Lymphoma: A Comparison with [18F]FDG PET/CT

Ist Teil von

• Molecular imaging and biology, 2022-06, Vol.24 (3), p.416-424

Ort / Verlag

Cham: Springer International Publishing

Erscheinungsjahr

2022

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Purpose This study aimed to evaluate the value of [ 68  Ga]Pentixafor PET/CT for the detection of lesions in central nervous system lymphoma (CNSL) patients before chemotherapy, during treatment and suspected CSNL recurrence, compared with 2-deoxy-2-[ 18 F]fluoro-D-glucose ([ 18 F]FDG) positron emission tomography/computed tomography (PET/CT). Procedures Twenty-six patients with newly or previously diagnosed CNSL who underwent [ 68  Ga]Pentixafor PET/CT were included retrospectively. Histopathological results, magnetic resonance imaging (MRI), and follow-up were used as the standard reference. The accuracy of lesion detection, maximum standardized uptake value (SUV max ) of tumors, and ratio of tumor-to-normal brain (T/N) with [ 68  Ga]Pentixafor PET/CT were calculated and compared to those obtained with [ 18 F]FDG PET/CT. CXCR4 expression was analyzed through immunohistochemistry. Results Of 26 patients, 18 were newly diagnosed with a total of 23 lesions, 4 had recurrent with 4 lesions, and 4 underwent a mid-term treatment assessment after 4 cycles of chemotherapy (3 achieved complete response (CR), 1 experienced progressive disease (PD) with a total of 8 lesions). Thirty-five lesions were all clearly detected with favorable contrast by [ 68  Ga]Pentixafor PET/CT (accuracy, 100%), consistent with the results of contrast-enhanced magnetic resonance imaging (CE-MRI). The SUV max of positive lesions in [ 68  Ga]Pentixafor PET/CT was correlated with tumor size ( r  = 0.555, P  = 0.001). In 21 patients, compared with [ 18 F]FDG PET/CT, [ 68  Ga]Pentixafor PET/CT showed a remarkably higher T/N ratio (21.93 ± 10.77 vs 4.29 ± 2.16, P  = 0.000) and detected 5 more lesions in the mid-term treatment assessment of patients ( P  = 0.026). The CXCR4 expression of CNSL lesions was correlated with SUV max of [ 68  Ga]Pentixafor PET/CT ( r  = 0.772, P  = 0.000). Conclusions CXCR4 - directed PET/CT using [ 68  Ga]Pentixafor, with excellent tumor-to-background contrast, might be a more promising agent for the detection of lesions in CNSL patients than [ 18 F]FDG PET/CT.